Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases

Human Gene Therapy

Volumn 13, Issue 10, 2002, Pages 1213-1223

  Wong, Richard J ^a   Joe, John K ^a   Kim, Se Heon ^a,b   Shah, Jatin P ^a   Horsburgh, Brian ^c   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Yonsei University College of Medicine   (South Korea)

^c MediGene   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ARTICLE; C3H MOUSE; CELL LINE; GENE THERAPY; HERPES VIRUS; HISTOLOGY; LYMPH NODE; LYMPH NODE METASTASIS; MALE; METHODOLOGY; MOUSE; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ASSAY; CANCER SURVIVAL; CERVICAL LYMPH NODE; CONTROLLED STUDY; DRUG EFFICACY; FLUORESCENCE MICROSCOPY; FOLLOW UP; HISTOPATHOLOGY; LYMPHATIC DRAINAGE; NONHUMAN; VIRUS INFECTION; VIRUS PLAQUE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE; GENE THERAPY; HERPESVIRIDAE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MICE; MICE, INBRED C3H; ANIMAL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

5 BROMO 4 CHLORO 3 INDOLYL BETA DEXTRO GALACTOPYRANOSIDE; ANTINEOPLASTIC AGENT; GREEN FLUORESCENT PROTEIN; NV 1023; NV 1066; ONCOLYTIC VIRUS; PYRANOSIDE; UNCLASSIFIED DRUG;

ANIMALIA; DNA VIRUSES; HERPESVIRIDAE; MARTES PENNANTI; MURINAE; SIMPLEXVIRUS;

EID: 0036019202     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303402320138998     Document Type: Article

References (22)

1. Cervical lymph node metastasis: Model for study of head/neck melanoma
2. Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer
3. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207)
4. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice
5. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy
6. Modification of the effects of continuous low-dose radiation by concurrent chemotherapy infusion
7. A defective HSV-1 vector expresses Escherichia coli-galactosidase in cultured peripheral neurons
8. Different metastatic modes of malignant melanoma implanted in the ear of young and old mice
9. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207)
10. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial
11. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents
12. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus)
13. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas
14. A new immunocompetent murine model for oral cancer
15. Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207
16. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1
17. Herpes simplex virus as an in situ cancer vaccine for the induction of specific antitumor immunity
18. Head and neck cancer
19. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207
20. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus
21. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma